Item 7.01. Regulation FD Disclosure. As previously reported, onAugust 17, 2020 ,Brickell Biotech, Inc. (the "Company") received a notice from theListing Qualifications Department of theNasdaq Stock Market ("Nasdaq") indicating that the Company was not in compliance with the$1.00 per share minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the "Rule"). OnJanuary 21, 2021 , the Company received a letter from Nasdaq notifying the Company that it had regained compliance with the Rule as a result of the closing bid price of the Company's common stock being at$1.00 per share or greater for the 11 consecutive business days fromJanuary 5, 2021 throughJanuary 20, 2021 . Accordingly, the Company has regained compliance with the Rule and Nasdaq considers the matter closed.
--------------------------------------------------------------------------------
© Edgar Online, source